May 17: Using RWE to Inform the Value and Affordability Assessment of Cell and Gene Therapies - In Person at ISPOR 2026
event-Short-Courses

May 17, 2026

Explore how real-world evidence can inform value, affordability, and access decisions for cell and gene therapies.

Cell and gene therapies (CGTs) have the potential to deliver transformative, long-term benefits through one-time treatment, often for severe or rare conditions. However, these therapies are frequently supported by limited clinical evidence, such as small or single-arm trials, creating uncertainty for payers related to eligible populations, appropriate comparators, durability of benefit, and relative effectiveness. These uncertainties are compounded by the high upfront costs of CGTs and concerns about affordability and budget impact.

Technical Topics Include:

  • The role of RWE in supporting economic evaluation of CGTs

  • Addressing evidence gaps related to eligibility, comparators, and natural disease progression

  • Evaluating relative effectiveness and durability of benefit using RWE

  • Payer archetypes focused on value, cost-effectiveness, and budget impact

  • Assessing internal and external validity of real-world data

  • Using RWE to inform payment models and outcome-based agreements

This Course Includes Tools and Concepts That Can Be Immediately Applied, Including:

  • Practical guidance on planning and generating RWE for CGTs

  • Examples of RWE use in payer decision-making and policy development

  • Frameworks for balancing access, value, and affordability

  • Real-world case examples illustrating RWE-informed economic evaluation

Participants will gain a clearer understanding of how RWE can be used to address payer uncertainty and support informed reimbursement and policy decisions for cell and gene therapies across diverse stakeholder contexts.

PREREQUISITE: This course requires familiarity with basic economic evaluation and HTA concepts and methodologies of pharmaceuticals.

 

LEVEL: Intermediate
TRACK:
Real World Data & Information Systems

This short course is offered in-person at the ISPOR 2026 conference. Separate registration is required. Registration coming soon. Visit the ISPOR 2026 Program page to learn more.

FACULTY MEMBERS

Daniel Gladwell, PhD
Chief Scientific Officer, HEOR
Lumanity
London, England

Antal T. Zemplenyi, MSc, MPH, PhD
Health Economist and Research Assistant Professor
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado
Aurora, CO, USA

Oriol Solà-Morales, MD, MSc, PhD
Chair Fundació HiTT
Health Innovation Technology Transfer (HiTT)
Barcelona, Spain

Renske MT ten Ham, PhD PharmD
Assistant Professor Health Economics
University Medical Center Utrecht (UMC Utrecht)
Utrecht, the Netherlands

 

Schedule:

LENGTH: 4 Hours | Course runs 1 day

Tuesday, 17 May 2026 | Course runs 1 Day

ISPOR short courses are designed to enhance knowledge and techniques in core health economics and outcomes research (HEOR) topics as well as emerging trends in the field. Short courses offer 4 or 8 hours of premium scientific education and an electronic course book. Active attendee participation combined with our expert faculty creates an immersive and impactful learning experience. Short courses are not recorded and are only available during the live course presentation.

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×